We found that HOXC10 may serve as a novel biomarker of KRAS-mutant lung cancer bone metastasis, implying the multifaceted role of HOXC10 in KRAS-mutant lung cancer bone metastasis and broadening the application of HOXC10-based therapy. Here, KRAS is linked to lung carcinoma.